Peptide Therapy
Ibutamoren (MK-677)
Ibutamoren is a potent, long-acting oral peptide focused on ghrelin receptors. It has been shown to increase the secretion of several hormones including GH and IGF-1. It is orally active and can be taken once a day. These are all benefits compared with other growth hormone stimulators. It is best prescribed to be taken before bed to maximize the body’s natural cycle of growth hormone and stimulate the pituitary gland during REM sleep.
What Is The Point Of Taking Ibutamoren?
A great thing about Ibutamoren is that it increases growth hormone levels with little or no increase in other hormones, such as cortisol. Cortisol suppresses the immune system, reduces wound healing, and impairs learning and memory, and it’s usually not good to have this hormone elevated. In addition, this peptide has shown to increase IGF-1 levels for up to 24 hours with a single oral dose.
Why Would I Want To Use Ibutamoren?
Based on the literature, Ibutamoren has been shown to be effective in raising growth hormone/insulin growth factor levels which helps to:
- Increase bone density
- Strengthen the cardiovascular system
- Increase muscle mass
- Improve ability to burn fat
- Increase sex drive
- Improve recovery and repair from injuries
- Regenerate nerve tissues
- Strengthen the immune system
- Improve cognition and memory
- Outperforms Sermorelin due to longer half-life and increased efficacy
- Patient Benefits Over Time
Benefits for patients on Ibutamoren shown over the first six weeks of protocol may include improvements in:
- Week 1: Quality of sleep
- Week 2: Recovery from workouts
- Week 3: Mental Clarity
- Week 4: Skin elasticity
- Week 5: Body Composition
What You Need To Know
Ibutamoren should not be used while pregnant or breastfeeding. Always tell your physician about all medications and supplements, especially corticosteroids and thyroid medications, that you are taking. Common side effects of Ibutamoren include increased hunger, slight muscle pain, flushing of the face; and less than 1 percent of patients report dizziness, headache, or hyperactivity.